Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBQD9H)

Drug Name

TAK-906 Drug Info

Synonyms

Trazpiroben; UNII-FH87H57Q4Y; FH87H57Q4Y; triazaspiro[4.5]decan-3-yl]methyl}benzoic acid; 1352993-39-5; 3-{[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-; Trazpiroben [INN]; Trazpiroben [USAN]; SCHEMBL318454; WHO 11123; (3-((1-Cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8 triazaspiro(4.5) decan-3-yl)methyl)benzoic acid; 3-[[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoic acid; Benzoic acid, 3-((1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro(4.5)dec-3-yl)methyl)-

Indication

Disease Entry	ICD 11	Status	REF
Diabetic gastroparesis	DA41.00	Phase 2	[1]

Cross-matching ID

PubChem CID: 54768846
CAS Number: CAS 1352993-39-5
TTD Drug ID: DMBQD9H

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Inhibitor	[2]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Dopamine D2 receptor (D2R)	DTT	DRD2	5.345	5.634	5.789	5.901
Dopamine D3 receptor (D3R)	DTT	DRD3	1.379	2.446	1.233	1.07

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Diabetic gastroparesis

ICD Disease Classification

DA41.00

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03544229) A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis. U.S. National Institutes of Health.
2	Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.